Skip to content
Search

Latest Stories

PDA investigates Boots pharmacists' pension entitlement concerns

PDA investigates Boots pharmacists' pension entitlement concerns

WBA recently moved Boots pension scheme to L&G in a £4.8 billion deal

The Pharmacists’ Defence Association (PDA) is probing major concerns arising from Boots' communications to pharmacists regarding the company's recently announced pension arrangements.


In November, Walgreens Boots Alliance (WBA), the parent company of Boots, transferred the Boots employees' pension scheme to the financial service provider Legal and General (L&G) in a £4.8 billion deal.

Boots notified staff that terms allowing an unreduced pension from age 60 have ceased immediately, following its agreement with L&G.

The PDA highlighted member concerns regarding Boots management's announcement that an unreduced pension from the age of 60 is a discretionary benefit and not guaranteed under the Boots Pension Scheme (BPS), contrary to some members' assumptions.

On December 7, the PDA communicated with affected members—those possessing pension benefits in the BPS, a final salary scheme closed to new entrants in 2010—explaining that the winding up of closed final salary schemes and securing benefits through an insurance policy is a standard procedure.

"Discretionary benefits are not protected unless explicitly included in the rules during the commencement of the winding-up process and buy-in," the PDA wrote.

PDA Union National Officer Paul Moloney said that his team has been evaluating various pieces of information, with a particular focus on the Trust Deed and Rules, which are deemed the definitive documents.

Moloney emphasised that these documents do describe the normal retirement age as 65. “However, we have also seen individual benefit statements from those members kind enough to send them to us. There is no doubt these communicate that a full pension is payable at 60,” he added.

"No mention is made that this is solely at the discretion of the trustees, and importantly, there is no indication that individuals should not rely on this arrangement still being in place upon their retirement,” he added.

Moloney said, "If benefit statements had included words to this effect, we would reluctantly have concluded that nothing could be done to safeguard the unreduced pension at 60. However, based on our examination, such language is absent."

"Our considered view, emphasising the information available to date, suggests a potential matter for resolution by the Pensions Ombudsman.”

However, the PDA advised members against taking additional steps, such as making a claim, pending further investigations by the PDA to determine whether the evidence supports the company's position.

"If not available, we will guide members on the steps to utilise the disputes procedure before filing complaints with the Ombudsman,” Moloney said in the letter.

The PDA plans to provide members with an update by the end of next week.

Boots and the Trustees of the Boots Pension Scheme announced an insurance transaction for increased certainty and security, according to the company.

“In the customary review, various pension options previously at the Trustee's discretion were assessed. Insured options, like death benefits for eligible dependants, were retained, while discretionary choices such as enhanced early retirement were discontinued,” Boots added.

In November, Boots closed three additional stores as part of its ongoing initiative to shutter 300 stores across the UK in the next 12 months.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less